309 related articles for article (PubMed ID: 20920997)
1. Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer.
Montagnani F; Chiriatti A; Licitra S; Aliberti C; Fiorentini G
Clin Colorectal Cancer; 2010 Oct; 9(4):243-7. PubMed ID: 20920997
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis.
Guo Y; Shi M; Shen X; Yang C; Yang L; Zhang J
Clin Colorectal Cancer; 2014 Jun; 13(2):110-8. PubMed ID: 24461997
[TBL] [Abstract][Full Text] [Related]
4. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
Skof E; Rebersek M; Hlebanja Z; Ocvirk J
BMC Cancer; 2009 Apr; 9():120. PubMed ID: 19386096
[TBL] [Abstract][Full Text] [Related]
6. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
Jackson NA; Barrueco J; Soufi-Mahjoubi R; Marshall J; Mitchell E; Zhang X; Meyerhardt J
Cancer; 2009 Jun; 115(12):2617-29. PubMed ID: 19382200
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
Moosmann N; Heinemann V
Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients.
Li W; Xu J; Shen L; Liu T; Guo W; Zhang W; Chen Z; Zhu X; Li J
BMC Cancer; 2014 Dec; 14():986. PubMed ID: 25527007
[TBL] [Abstract][Full Text] [Related]
9. Current status of capecitabine in the treatment of colorectal cancer.
Rothenberg ML
Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
[TBL] [Abstract][Full Text] [Related]
10. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
Fuchs CS; Marshall J; Mitchell E; Wierzbicki R; Ganju V; Jeffery M; Schulz J; Richards D; Soufi-Mahjoubi R; Wang B; Barrueco J
J Clin Oncol; 2007 Oct; 25(30):4779-86. PubMed ID: 17947725
[TBL] [Abstract][Full Text] [Related]
11. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
Vasile E; Masi G; Fornaro L; Cupini S; Loupakis F; Bursi S; Petrini I; Di Donato S; Brunetti IM; Ricci S; Antonuzzo A; Chiara S; Amoroso D; Andreuccetti M; Falcone A
Br J Cancer; 2009 Jun; 100(11):1720-4. PubMed ID: 19436300
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.
Ocvirk J; Rebersek M; Boc M
Anticancer Res; 2011 May; 31(5):1777-82. PubMed ID: 21617239
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
Mazard T; Ychou M; Thezenas S; Poujol S; Pinguet F; Thirion A; Bleuse JP; Portales F; Samalin E; Assenat E
Cancer Chemother Pharmacol; 2012 Mar; 69(3):807-14. PubMed ID: 22037922
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
Köhne CH; De Greve J; Hartmann JT; Lang I; Vergauwe P; Becker K; Braumann D; Joosens E; Müller L; Janssens J; Bokemeyer C; Reimer P; Link H; Späth-Schwalbe E; Wilke HJ; Bleiberg H; Van Den Brande J; Debois M; Bethe U; Van Cutsem E
Ann Oncol; 2008 May; 19(5):920-6. PubMed ID: 18065406
[TBL] [Abstract][Full Text] [Related]
15. Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
Cartwright T; McCollum D; Boehm KA
Am J Clin Oncol; 2010 Jun; 33(3):307-13. PubMed ID: 20375835
[TBL] [Abstract][Full Text] [Related]
16. XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
Uygun K; Bilici A; Kaya S; Oven Ustaalioglu BB; Yildiz R; Temiz S; Seker M; Aksu G; Cabuk D; Gumus M
Asian Pac J Cancer Prev; 2013; 14(4):2283-8. PubMed ID: 23725128
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
18. XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer.
Sakar B; Gumus M; Basaran M; Argon A; Ustuner Z; Ustaoglu MA; Saglam S; Guney N; Tenekeci AN; Aykan NF
Oncology; 2007; 73(5-6):298-304. PubMed ID: 18477855
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI).
Ding HH; Wu WD; Jiang T; Cao J; Ji ZY; Jin JH; Wang JJ; Song WF; Wang LW
Tumour Biol; 2015 May; 36(5):3361-9. PubMed ID: 25534239
[TBL] [Abstract][Full Text] [Related]
20. A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer.
Lim SH; Kim TW; Hong YS; Han SW; Lee KH; Kang HJ; Hwang IG; Lee JY; Kim HS; Kim ST; Lee J; Park JO; Park SH; Park YS; Lim HY; Jung SH; Kang WK
Br J Cancer; 2015 Nov; 113(10):1421-6. PubMed ID: 26505681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
